Mitchell Kapoor
Recent Articles
Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise 05/04/2026
H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout.
Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028 04/20/2026
MeiraGTx Holdings plc. (MGTX:NASDAQ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline 03/26/2026
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry.
Therapeutics Company Advances Gene Therapy Breakthrough 10/09/2025
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
New Remission Data on MG Patients Compelling 09/05/2025
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report.
LA Biotech Unveils New Patented Nicotinamide Riboside Chloride 07/15/2024
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report.
